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Fig. 1: Least square means of RV by categorical patient order 
(corrected for CTV original and centre). 
 
Conclusions: Central review significantly improved the uniformity of 
the CTV delineation in the first ten rectal cancer patients submitted 
per centre. The high agreement on CTV delineations from the 
beginning of the review period and the fact that some centres 
submitted a low number of cases may explain the lack of a learning 
curve over the whole period. Further analysis of the data can highlight 
current ambiguities in the delineation guidelines and can help us in 
further improving these. 
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Purpose/Objective: Research on quality of cancer care (QoCC) during 
the last decade has demonstrated that the increase in knowledge on 
treatments with proven efficacy does not directly translate into 
optimal treatment delivery to patients. On the other hand, data 
describing the proportion of patients with rectal cancer (RC) who 
benefit of up-to-date evidence-based diagnostic-treatment procedures 
are still scarce in the literature. Aims of the present study are: 1) to 
describe the methods used for the selection of RC specific quality 
indicators (QI); 2) to analyse three QI concerning patients diagnosed 
with a new RC in Southern Switzerland and receiving neo-adjuvant 
radiation therapy (RT). 
Materials and Methods: QI have been developed in the context of a 
QoCC project as follows: seek and nomination of multidisciplinary RC 
Working Group, selection of QI on an evidence-based manner, choice 
of QI through a two-rounds Delphi-process and validation of final QI by 
an international Advisory Board (consensus ≥ 70%). Patients with RC 
incident from 2011 to 2012 were retrieved from the files of Ticino 
Cancer Registry. According to ICD-O-III tumour classification, 
epithelial tumours were included, but neuroendocrine, GIST, sarcoma, 
lymphoma. Additional information was extracted from the single 
pathology and RT records in both public and private hospitals. QI will 
be presented as proportion with the corresponding 95% confident 
intervals. The numerator and the denominator will be defined 
according to the definition of each QI. 
Results: We initially considered 51 rectum-specific QI, of which 15 
were RT-related. At the end of the whole process, 21 QI were finally 
validated (RT-related, N=9). Results of patients diagnosed with RC in 
2011-2012 will be presented for the following 3 RT-related QI: 1) 
proportion of patients with RC for which the request for the 
pathological examination includes the information of neo-adjuvant 
RT (in patients with RC undergoing neo-adjuvant RT and surgery); 2) 
proportion of patients with locally advanced RC undergoing neo-
adjuvant RT (in patients with locally advanced RC undergoing surgery; 
3) proportion of patients with RC and undergoing neo-adjuvant RT 
operated within 6-8 weeks after the end of neo-adjuvant RT (in 
patients with RC undergoing neo-adjuvant RT and surgery).  
Conclusions: QI are mandatory not only for clinicians, but also for 
stakeholders and patients. QI should be defined, developed and tested 
with scientific evidence-based rigor in a careful and transparent 
manner. The present QI study is based on expertise and active 
involvement of local health care providers and international experts 
representing all major disciplines (epidemiology, pathology, radiology, 
gastroenterology, surgery, radiation oncology, oncology, nuclear 
medicine), thus increasing quality, acceptance and translation of 
results into the daily clinical practice. 
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Purpose/Objective: To tailor treatment for locally advanced rectal 
cancer (LARC) an early accurate prediction of tumor response after 
preoperative chemoradiotherapy (CRT) is required. In literature, 
response prediction for LARC is mainly based on PET-imaging, but 
these studies are small and rarely validated. This study provides a 
prediction model based on a multicentric analysis of LARC response 
with clinical and sequential PET data of before and during treatment 
from three different institutes.  
Materials and Methods: In total, 112 patients from one institute were 
used to train the prediction model.The model was tested on 
respectively 78 and 28 patients from two different institutes. All LARC 
patients were prospectively accrued between 2007 and 2011 and 
received long-course radiotherapy (45-55 Gy) and concomitant 
chemotherapy. Two PETCT scans were made, pretreatment (day0) and 
halfway treatment (day 15). Tumors were semi-automatically 
contoured using a signal-to-background based threshold method. 
Extracted PET features of the two time points were SUVmean, SUVmax, 
metablic tumor volume (MTV) and maximal tumor diameter. Response 
indices between day0 and day 15 were calculated. They were 
analyzed together with age and gender of the patient and cT- and cN-
stage. The endpoint for prediction was pathologic complete response 
(pCR) defined as ypT0N0, based on pathology reviews of the resected 
specimen. Eleven patients who were also included in a wait-and-see 
study were considered to have pCR when they were recurrence free 
for at least 1 year. Significant predictors from a univariate Mann–
Whitney U test were included in a multivariate model based on 
logistic regression to predict tumor response. Performance of the 
model was expressed as a bootstrapped AUC (Area Under the Curve) of 
the Receiver Operating Characteristic (ROC).  
Results: The data distributions, number of missing values and pCR 
rates were similar between the institutes (Table). Based on the 
univariate analysis and outcome of the logistic regression, cT- and cN-
stage, maximal diameter at day15 and response index of SUVmax were 
selected as predictors. A nomogram was deducted from this model 
(Figure), resulting in performances of 0.78 for the training dataset and 
0.69 and 0.64 for the smaller validation datasets.  
 
 Conclusions: Sequential PET-imaging has predictive power for 
response after chemoradiotherapy in LARC patients. Application of the 
developed model in other institutes is less accurate, but still useful 
for tailored decision making. When patients are assigned to risk groups 
for an uncomplete response, high risk patients may be candidates for 
radiotherapy boost and adjuvant chemotherapy strategies, while the 
low risk patients may be followed-up with a wait-and-see policy, 
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increasing the quality of life. A prospective trial to test decision 
making with the model versus a controlled group with standard 
treatment is the next step towards implementation of a decision 
support system for rectal cancer.  
 
  
 SYMPOSIUM: FUTURE RADIOTHERAPY CLINICAL 
TRIALS: SALT, PAPRIKA AND MOLECULAR SIGNA-
TURES AND RT  
  
SP-0423   
The implications & challenges for clinical trial design involving 
radiotherapy 
T. Maughan1 
1University of Oxford, Gray Institute for Radiaton Oncology & Biology, 
Department of Oncology  
 
Modern radiotherapy research is built on well validated biological and 
physical hypotheses which will be tested in the clinical trial.  The trial 
design must enable the investigator to obtain a clear answer to the 
primary trial objective, through clear enunciation of the primary 
hypothesis, the endpoint to be measured and an appropriate 
statistical design to enable the hypothesis to be evaluated in a way 
which is reliable. The extreme heterogeneity of cancer is leading 
some investigators to think that conventional clinical trial 
methodology is outmoded and that fundamentally different 
approaches are required. Individualisation of therapy on the basis of 
tumour genotype, imaging or both is portrayed as the goal of modern 
cancer therapy. Individualisation of radiotherapy occurs in every case 
through the treatment planning process and within clinical trials this 
must be undertaken within the constraints of a prospectively 
optimised and agreed radiotherapy treatment protocol and 
commensurate RT quality assurance process to be delivered before 
and during the trial. Similarly biomarker or imaging based treatment 
allocation or randomisation requires the use of rigorous technical 
delivery of the assay or scan and an agreed method of interpretation 
of the outcome. In phase 1 drug radiation trials, delays while waiting 
for assessment of radiotherapy toxicity risk making such studies too 
slow and relatively early dose escalation and ‘flip-flop’design 
evaluating two novel agents in alternating dose escalation cohorts is 
an efficient design. Multi-stage trial designs can speed up the phase 
II/III evaluation of novel therapies, while enabling early termination 
for futility. The SCOPE-1 trial of the addition of cetuximab to 
chemoradiotherapy for oesophageal cancer is an example. Prospective 
molecular sstratification of patients for intervention trials relevant to 
the specific abnormalities in their tumour can be designed but require 
extensive collaboration and large numbers. Such designs are coming 
into stratified drug trials such as the FOCUS4 study in metastatic 
colorectal cancer and the applicability to radiotherapy studies will be 
discussed.  
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Integration of molecular imaging techniques into therapy selection 
strategies and radiation treatment planning can serve several 
purposes. First, pretreatment assessments can steer decisions about 
radiotherapy modifications or combinations with other modalities. 
Second, biology-based objective functions can be introduced to the 
radiation treatment planning process by co-registration of functional 
imaging with planning CT-scans. Thus, customized heterogeneous dose 
distributions can be generated with escalating doses to tumor areas 
where radiotherapy resistance mechanisms are most prevalent. Third, 
monitoring of temporal and spatial variations in these radiotherapy 
resistance mechanisms early during the treatment can discriminate 
responders from non-responders. With such information available 
shortly after the start of the treatment, modifications can be 
implemented or the radiation treatment plan can be adapted tailing 
the biological response pattern. 
Currently, these strategies are in various phases of clinical testing, 
mostly in single-center studies but more and more also in multi-center 
set-up. Ultimately, this should result in availability for routine clinical 
practice requiring stable production and accessibility of tracers, 
reproducibilty and standardization of imaging and analysis methods 
and general availability of knowledge and expertise. Small studies 
employing adaptive radiotherapy based on functional dynamics and 
early response mechanisms demonstrate promising results. This 
approach is closest to large scale clinical testing with good prospects 
for success. 
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The definition of quality in radiation therapy largely remains poorly 
defined, understood and often confused with the issues of safety.  
While safety and quality are on many levels inseparable, there is a 
clear distinction and there can be delivery of safe treatments 
according to physician prescription in radiation therapy which are of 
insufficient quality to meet the treatment goals.  High quality clinical 
operations can be defined as those which minimize variations and 
uncertainty in patient treatments and result in consistent 
outcomes. In radiation therapy, treatment consists of multiple 
components (consultation, treatment selection, immobilization, 
imaging for planning, contouring, planning, etc.).  Relatively large 
variation and uncertainty in any one of these steps contribute to the 
overall degradation of treatment quality.  The degradation of quality 
results in uncertainty in patient outcomes.  Figure 1 a) shows an 
example distribution of patient treatments.  On one end of the 
spectrum is overdose of critical structures, in middle are the majority 
of patient treatments which result in clinical benefit without 
unexpected side effects,and on the other side of the spectrum is 
under dose of target volumes.  The over dose and under dose is clearly 
bad, but the two regions between clinical benefit and over dose and 
under dose, respectively, have clinical uncertainty. Patients falling in 
these uncertainty regions may or may not have clinical complications 
or poor tumor control. Patients falling in extreme over or under dose 
regions are typically infrequent and these are extreme cases that 
typically are widely publicized.  However, it is unclear how many 
patients fall in the uncertainty regions and potentially have 
compromised outcomes.  It is important to note that the outcomes in 
the uncertainty region are often considered as expected and accepted 
treatment outcomes, though possibly avoidable. 
